From PsychonautWiki
(Redirected from E)
Jump to navigation Jump to search
Summary sheet: Escaline
Chemical Nomenclature
Common names Escaline
Substitutive name 3,5-methoxy-4-ethoxyphenethylamine
Systematic name 2-(4-Ethoxy-3,5-dimethoxy-phenyl)-ethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 20 - 30 mg
Light 30 - 50 mg
Common 50 - 100 mg
Strong 100 - 150 mg
Heavy 150 mg +
Total 8 - 12 hours
Onset 90 - 120 minutes
After effects 3 - 5 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


3,5-Dimethoxy-4-ethoxyphenethylamine (commonly known as Escaline) is a synthetic psychedelic substance of the phenethylamine chemical class that produces psychedelic effects when administered. It is a closely related structural analog of mescaline with which it shares many common properties.

Escaline was first synthesized and reported in the scientific literature by Benington, et al., in 1954, but was later re-examined in the laboratory of David E. Nichols who prepared a series of mescaline analogues, including proscaline, jimscaline, isoproscaline, and others.

The effects of escaline were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story. He lists the dosage range as 40 mg to 60 mg orally and describes the duration of action to be 8–12 hours.[1] Shulgin states that escaline “differs from mescaline in that the onset of action is quicker (within the first hour) and there is no nausea noted, but otherwise the time course, and much of the qualitative content, is quite similar.”[2]


Escaline, or 3,5-dimethoxy-4-ethoxyphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino -NH2 group through an ethyl chain. Escaline contains two methoxy functional groups CH3O- which are attached to carbons R3 and R5 as well as an additional ethoxy group at carbon R4 of the phenyl ring. Escaline is the 4-ethoxy analog of mescaline.


Further information: Serotonergic psychedelic

Escaline's agonist activity at the serotonin 5-HT2A receptor is known to be 5-8 times greater than that of mescaline. [3][4] The effects of this compound are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

In comparison to mescaline, this compound has significantly more negative physical side effects, less insightful cognitive effects and less complex visual effects. The effects listed below are based on the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy amount of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational escaline use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because escaline is a research chemical with a very brief history of human usage. Anecdotal evidence from people within the community who have tried escaline suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

Escaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of escaline is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). Escaline presents cross-tolerance with all psychedelics, meaning that after the consumption of escaline all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when taken with other substances. The following lists some known dangerous combinations, but cannot be guaranteed to include all of them. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.



This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Germany: Escaline is controlled under the NpSG, as it is a derivative of 2-Phenethylamine.[6] Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.[7][8]
  • United States - Escaline is unscheduled in the U.S. but may be illegal via the Federal Analogue Act.
  • United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[9]

See also

External links


  1. | #72 E; ESCALINE
  2. | Psychotomimetic Drugs: Structure-Activity Relationships
  3. | Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.
  4. | Psychotomimetic Drugs: Structure-Activity Relationships
  5. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  9. Psychoactive Substances Act 2016 ( |